Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. BiondVax Pharmaceuticals Ltd. (BVXV) Message Board

Review Shows AI Could Be Pivotal in Infectious Dis

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 122
(Total Views: 220)
Posted On: 07/28/2023 4:44:13 PM
Avatar
Posted By: NetworkNewsWire
Review Shows AI Could Be Pivotal in Infectious Disease Prevention

The worst of the coronavirus pandemic may be in the past, but it showed just how badly a fast-spreading infectious disease could affect the world. Most countries were woefully unprepared to deal with a medical event of that magnitude, and for the most part, the world still isn’t equipped to deal with such a pandemic.

Millions of lives were lost worldwide during the pandemic, and to this day thousands of people across the world are still dealing with long Covid symptoms. Researchers recently discussed the possibility of using machine learning and artificial intelligence to prevent future disease outbreaks and pandemics.

Published in the “Science” journal, the review covered the challenges involved in predicting and preventing infectious disease outbreaks and the future role that artificial intelligence could play. The study noted that infectious diseases still present a global challenge that our advancements in pharmaceuticals, molecular genetics and computing power haven’t been able to address.

Infectious diseases such as ebola, Zika, Marburg virus and H5N1 influenza have the potential to cripple the global economy and, even more significantly, take countless lives if they get out of hand. Furthermore, dangerous pathogens such as multidrug-resistant tuberculosis and carbapenem-resistant Enterobacteriaceae (CRE) present a constant risk of widespread disease outbreaks.

As the world becomes even more interconnected, it is crucial that we develop ways of preventing infectious disease outbreaks before they spread across borders and cause immense stress on already-stretched healthcare systems. Leveraging increasingly advancing software could give us the tools we need to detect infectious diseases as early as possible and deploy preventative and treatment options before they proliferate.

Machine learning (ML) and artificial intelligence (AI) present the most attractive options as they allow for the study and analysis of gargantuan data sets. ML is already being used to train computers to make more accurate predictions and has aided in searches of small-molecule databases.

Using tools such as machine learning makes it possible for scientists and physicians to examine genetic information in the greatest detail to predict antigens and discover crucial molecular structures that control immune responses and interactions between pathogens and hosts.

Aside from their predictive features, AI and ML can also help in the development of infectious disease treatments. For instance, systems such as NVIDIA’s BioNeMo and GPT-4 can aid in our understanding of fundamental chemical and biological dynamics by combining various scientific data streams.

Although AI and ML are still relatively new fields, they have already played a major role in modernizing medicine and improving treatment outcomes. The technology will most likely be as useful in developing preventative and treatment strategies for infectious diseases.

In the meantime, companies such as BiondVax Therapeutics Ltd. (NASDAQ: BVXV) are working to bring to market immunotherapies targeting infectious diseases so that their outbreaks affect as few people as possible.

NOTE TO INVESTORS: The latest news and updates relating to BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are available in the company’s newsroom at https://ibn.fm/BVXV

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer




(0)
(0)




BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us